SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Starfighters Space Inc

Starfighters Space Inc. ($FJET) is experiencing extreme volatility following its recent NYSE American listing and a year-end corporate update. Community discussion is sharply divided between those calling it a "pure pump and dump" driven by its ultra-low float and IPO frenzy, and optimistic bulls expecting further parabolic moves amidst strong momentum in the space sector.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as the community eagerly awaits the launch of its BlueBird 6 satellite, a crucial step in deploying its global cellular broadband network. Bulls highlight the transformative technology and accelerating launch cadence, while bears debate the current valuation and anticipate profit-taking, fueling intense discussion across the space sector.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending due to its record-breaking 21st successful Electron launch and a substantial government contract for missile-tracking satellites, solidifying its new identity as a defense prime. This pivotal shift, coupled with recent analyst upgrades and strong sector tailwinds from broader space enthusiasm and speculation around a SpaceX IPO, fuels significant bullish sentiment and ambitious price targets among investors, though some caution exists regarding its rapid ascent and recent insider activity.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is surging in conversation after receiving FDA approval for its oral Wegovy pill, marking the first GLP-1 based oral therapy for weight management. The community widely views this as a significant catalyst, anticipating a substantial market advantage and potential for the stock to rebound, especially considering the product's convenience over injectables amidst a highly competitive sector.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is trending with significant anticipation for NASA's Lunar Terrain Vehicle (LTV) contract award, a sentiment amplified by recent analyst upgrades and strategic acquisitions. The community is largely bullish, often dismissing typical profit-taking and insider selling as routine or short-seller FUD, expecting continued momentum within the burgeoning space exploration sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is currently trending due to anticipation surrounding its upcoming showcase of commercial quantum computing technology at CES 2026, emphasizing real-world applications and its leadership in optimization. This excitement is further fueled by recent positive analyst coverage and increased institutional investment, positioning the company as a potential future leader in the quantum space. However, a significant portion of the community views the rapid price movement as speculative, citing concerns over current revenue and valuation driven by market hype within the broader quantum sector.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is currently trending following news that the Pipeline Hazardous Materials Safety Administration has approved its Las Flores Pipeline restart plan, a key regulatory decision shifting oversight to federal authorities. This development is fueling strong bullish sentiment among traders who anticipate a potential short squeeze and significant price appreciation for the company's long-stalled California offshore oil project. The community is actively discussing the stock's potential to rebound significantly as a major regulatory hurdle has been addressed.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Ordinary Shares - New

BriaCell Therapeutics Corp

BriaCell Therapeutics is trending due to recent positive clinical data from its Phase 2 and ongoing Phase 3 trials in metastatic breast cancer, bolstered by FDA Fast Track status and recognition from Nature Medicine. However, community discussions are sharply divided, with many expressing frustration over a history of frequent stock offerings and reverse splits that have led to significant investor dilution. This creates a contentious environment where the scientific advancements in cancer immunotherapy are weighed against past shareholder value impacts.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending amid significant discussion following its acquisition of cybersecurity startup Armis, a move aimed at bolstering its AI-powered security platform. Community sentiment is notably split: many view it as a strategic long-term play that enhances ServiceNow's enterprise AI and workflow automation, while others question the valuation and are concerned about the immediate market reaction. This corporate action, alongside a recent 5-for-1 stock split, is driving varied investor perspectives on its market position.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corp. is actively discussed following the FDA's acceptance of the FUROSCIX ReadyFlow Autoinjector sNDA, targeting a July 2026 decision, alongside the launch of Afrezza in India. Community sentiment is mixed, with optimism for potential new revenue streams and the ongoing success of their United Therapeutics partnership contrasting sharply with frustration over perceived management inefficiencies, recent executive share sales, and the stock's historical underperformance relative to other biotech peers. Investors are keenly watching if these developments will finally translate the company's core Technosphere platform into sustained shareholder value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

First Week of February 2026 Options Trading For Catalyst Pharmaceuticals (CPRX)

Investors in Catalyst Pharmaceuticals Inc (Symbol: CPRX) saw new options begin trading this week, for the February 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and...

Toth Financial Advisory Corp Has $42,000 Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Toth Financial Advisory Corp trimmed its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 96.5% in the third quarter, according to its most recent Form 13F filing...

CPRX vs. DSNKY: Which Stock Is the Better Value Option?

Molly Harper Takes Money Off The Table, Sells $621K In Catalyst Pharmaceuticals Stock

Wall Street Analysts See a 42.62% Upside in Catalyst (CPRX): Can the Stock Really Move This High?

The mean of analysts' price targets for Catalyst (CPRX) points to a 42.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?

Here is how ADC Therapeutics SA (ADCT) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of "Buy" by Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have been assigned an average rating of "Buy" from the ten research firms that are currently covering the firm, MarketBeat.com...

Catalyst Pharmaceuticals (NASDAQ:CPRX) Director Molly Harper Sells 26,746 Shares

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) Director Molly Harper sold 26,746 shares of the business's stock in a transaction that occurred on Friday, December 12th. The stock was...

If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Current Price	$24.36
Prev Close	$24.31
Open	$24.34
Dividend Yield	0.00%
50-Day Moving Average	$22.32
Beta	0.92
Avg. Volume	1.47M
PE Ratio	14.19

52-Week High	$26.58
52-Week Low	$19.05
Market Capitalization	$2.99B
EPS (Annual)	$1.31
Price to Book	3.26
Revenue Per Employee	$2.72M
Enterprise Value/EBITDA	N/A

CPRX
Catalyst Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CPRX News

CPRXCatalyst Pharmaceuticals Inc